Similar articles

• Mesenteric vein thrombosis in a patient heterozygous for factor V Leiden and G20210A prothrombin genotypes.

  Karmacharya P, Aryal MR, Donato A. Karmacharya P, et al. World J Gastroenterol. 2013 Nov 21;19(43):7813-5. doi: 10.3748/wjg.v19.i43.7813. World J Gastroenterol. 2013. PMID: 24282370 Free PMC article.
• The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.

  Sayinalp N, Haznedaroğlu IC, Aksu S, Büyükaşik Y, Göker H, Parlak H, Ozcebe OI, Kirazli S, Dündar SV, Gürgey A. Sayinalp N, et al. Clin Appl Thromb Hemost. 2004 Jul;10(3):265-70. doi: 10.1177/107602960401000309. Clin Appl Thromb Hemost. 2004. PMID: 15247984
• The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.

  Gessoni G, Valverde S, Gessoni F, Valle R. Gessoni G, et al. Blood Transfus. 2015 Oct;13(4):666-8. doi: 10.2450/2015.0224-14. Epub 2015 Jan 29. Blood Transfus. 2015. PMID: 25761318 Free PMC article. No abstract available.
• Factor V Leiden.

  Van Cott EM, Khor B, Zehnder JL. Van Cott EM, et al. Am J Hematol. 2016 Jan;91(1):46-9. doi: 10.1002/ajh.24222. Epub 2015 Nov 17. Am J Hematol. 2016. PMID: 26492443 Review.
• [National evaluation of the diagnosis of activated protein C resistance].

  Montiel-Manzano G, de la Peña-Díaz A, Majluf-Cruz A, Cesarman-Maus G, Corona-de la Peña N, Cruz-Cruz D, Gaminio E, Martínez-Murillo C, Mayagoitia T, Miranda-Peralta E, Poblete T, Quintana-Martínez S, Ramírez R, Razo D, Ruiz de Chávez-Ochoa A, Reyes-Núñez VA, Salazar R, Vicencio-Santiago GV, Villa R. Montiel-Manzano G, et al. Rev Invest Clin. 2003 May-Jun;55(3):358-69. Rev Invest Clin. 2003. PMID: 14515684 Review. Spanish.